Bulletin of Environment, Pharmacology and Life Sciences
Bull. Env. Pharmacol. Life Sci., Spl Issue [2] 2023: 371-375.

Online ISSN 2277-1808
Journal's URL:http://www.bepls.com
CODEN: BEPLAD

ORIGINAL ARTICLE **OPEN ACCESS**

Visual Prognosis Prediction in Retinal Vein Occlusion: Insights from Optical Coherence Tomography Biomarkers

Anjali D. Patil, Girish A. Gadre and Gaurav H. Khade
Department of Ophthalmology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Deemed To Be University, Karad

ABSTRACT

Despite breakthroughs in treatment, retinal vein occlusion (RVO) poses substantial hurdles in determining visual prognosis. Optical coherence tomography (OCT) is a promising biomarker-based prognostication method. With a focus on high-risk biomarkers, the objective of this research was to assess the predictive utility of pre- and post-injection (Anti-VEGF) OCT findings in predicting visual prognosis among RVO patients. On 100 patients with an RVO diagnosis, a prospective analysis was carried out. OCT imaging was done both before and after the injection to evaluate a number of characteristics, such as intraretinal cyst existence, macular volume, and central retinal thickness (CRT). The relationships between OCT biomarkers and visual results were established by statistical analysis, such as subgroup analyses and correlation studies. The baseline CRT measured 510µm, and the average age was found to be 58.4 years. Over the course of 12 weeks, post-injection alterations showed a steady reduction in CRT and MV. Greater post-treatment decreases in CRT/MV were found to be strongly correlated with increased visual acuity ($p < 0.001$). Based on RVO type, subgroup analysis revealed diverse treatment responses, with CRVO patients showing more significant decreases in CRT and MV. In conclusion, OCT measurements showed a strong relationship with improvements in visual acuity in RVO patients receiving anti-VEGF therapy, especially reductions in CRT and MV after treatment. These results highlight the potential of OCT indicators as visual prognosis predictors and point to the need for their incorporation into clinical decision-making for individualized RVO treatment.

Key words: *Retinal vein occlusion, Optical coherence tomography, Biomarkers, Visual prognosis, Anti-VEGF*

Received 30.09.2023 Revised 25.10.2023 Accepted 31.12. 2023

INTRODUCTION

Retinal vein occlusion (RVO), which includes central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO), is a common vascular condition that can impair vision. These illnesses have a deleterious effect on retinal blood flow, which can result in macular edema, retinal ischemia, and eventually blindness [1]. Although there have been improvements in treatment techniques, prognostic indicators need to be further investigated because it is still difficult to predict visual outcomes for RVO patients.

Pathophysiology of RVO: RVO's pathophysiology involves a number of different pathways. RVO is more likely in people with retinal vein thrombosis, which is frequently caused by compression at arteriovenous crossings [2]. As a result, poor venous drainage results in ischemia, edema, and hemorrhages, which in turn lead to changes in the structure and function of the retina [3]. The intricate pathophysiology of RVO highlights how difficult it is to forecast the condition's visual prognosis.

Landscape of Treatment

The main goals of current treatment approaches are to control side effects and stop the disease from getting worse. Targeting vascular leakage and neovascularization, anti-vascular endothelial growth factor (VEGF) therapy has completely changed the management of recurrent vein occlusion (RVO) [4]. Anti-VEGF intravitreal injections, such as aflibercept and ranibizumab, have shown promise in decreasing macular edema and enhancing visual acuity [5]. However, the necessity for trustworthy prognostic markers is highlighted by the variation in each patient's response to treatment.

Obstacles in Predicting Prognoses

Though advances have been made in imaging modalities such as optical coherence tomography (OCT), precise visual outcome prediction in RVO is still challenging. Merely relying on clinical measures might not adequately encompass the intricacies of illness advancement and therapeutic reaction. Finding reliable indicators in imaging parameters—especially OCT—becomes apparent as a vital path toward improving prognosis in RVO patients.

OCT's Function in Prognosis:

OCT provides non-invasive, high-resolution imaging of the retinal structures, allowing for the precise measurement of important parameters such as macular volume and central retinal thickness as well as a thorough evaluation of macular morphology [6]. Finding biomarkers that are correlated with functional visual outcomes in RVO patients is a promising application of this imaging technology. Visualizing and tracking changes in retinal architecture after therapy offers important information into how the disease progresses and how well therapy works.

It is still difficult to predict the visual prognosis in RVO patients, despite improvements in therapy techniques. OCT-based biomarkers need to be further investigated in order to improve prognostication and optimize treatment approaches because of the complex interactions between pathophysiological systems, the heterogeneity in therapy responses, and the limits of existing prognosis solutions.

MATERIAL AND METHODS

The Process of Choosing Patients and Designing a Research

One hundred patients with RVO, including those with central and branch retinal vein occlusion (BRVO and CRVO), were enrolled in this prospective research. The tertiary care center provided patients for recruitment between 2021-2022. Individuals between the ages of 18 and 75 who had a confirmed diagnosis of RVO based on fundus examination and fluorescein angiography met the inclusion criteria. Individuals having concurrent ocular diseases impairing visual acuity or a history of prior retinal operations were excluded.

OCT Imaging and Data Collection: Using OCT Device spectral-domain optical coherence tomography (SD-OCT) imaging was performed on all registered patients. Prior to starting any treatment, baseline imaging was carried out to measure variables such as intraretinal cyst existence, macular volume (MV), and central retinal thickness (CRT). Post-injection imaging was performed according to a routine methodology at predetermined intervals after anti-VEGF therapy.

Anti-VEGF Treatment Protocol: In accordance with the conventional treatment protocol, patients were administered intravitreal injections of anti-VEGF drugs, such as ranibizumab or aflibercept. The treating ophthalmologist decided on the frequency of injections and follow-up visits. After the start of treatment, post-injection OCT imaging was carried out at predetermined intervals (e.g., 4, 8, and 12 weeks).

Statistical Techniques and Data Analysis

Specialized software was used to do a quantitative research of the OCT parameters (CRT and MV) [SPSS Version 21]. To establish a correlation between changes in OCT biomarkers and visual acuity results, statistical studies were conducted. To evaluate the relationship between improvements in visual acuity and post-injection changes in CRT/MV, linear regression models were utilized. To investigate differences in treatment response, subgroup analyses based on age, gender, and baseline characteristics were carried out. Ethical Aspects and Informed Consent: The Declaration of Helsinki's guiding principles were followed in this investigation. Before starting the trial, approval from the ethics committee and institutional review board (IRB) was acquired. All participants gave their informed consent after being informed about the research's protocol, possible hazards, and rewards for taking part.

Data handling and confidentiality: Anonymized patient information was safely kept in a special database that was only accessible by authorized research participants. Throughout the duration of the trial, patient information was kept private and confidential.

RESULTS

Table 1: RVO Patients' Baseline Features

The baseline characteristics table gives important details on the initial measures and patient demographics for individuals with RVO. Patients were 58.4 years old on average, and the illness lasted 8.6 months on average. Baseline values for macular volume (MV) and central retinal thickness (CRT) were 9.7 mm^3 and 510μm, respectively. These measures show the typical profile of RVO patients at the beginning of the research and provide a point of reference for further studies.

Table 2: OCT Parameter Variations Following Anti-VEGF Therapy

The changes in OCT parameters that were noted in RVO patients after receiving anti-vascular endothelial growth factor (anti-VEGF) therapy are shown in this table. Over the course of the 12-week treatment period, it demonstrates a progressive reduction in both macular volume (MV) and central retinal thickness (CRT). Four weeks after the start of the treatment, there was an average MV change of 2.5mm^3 and CRT reduction of 82μm. At 12 weeks, the mean CRT reduction was 175μm, and the MV change was 5.7mm^3. These reductions were getting bigger. These results demonstrate how well anti-VEGF medication works to lessen retinal edema and morphological alterations.

Table 3: OCT Parameter Correlation with Improved Visual Acuity

The relationship between improvements in visual acuity and changes in OCT parameters (CRT and MV) in RVO patients is seen in this table. Greater reductions in CRT/MV post-treatment are significantly correlated with better visual acuity, as indicated by the strong positive correlation coefficients (0.72 for

CRT and 0.68 for MV). This highlights the potential of these metrics as predictors of visual prognosis in RVO patients following anti-VEGF medication, as it implies that greater decreases in retinal thickness and volume are associated with better visual results.

Table 4: RVO Type-Based Subgroup Analysis: There were significant variations in the response to treatment when the subgroup analysis was conducted based on the type of retinal vein occlusion (BRVO/CRVO). When compared to patients with branch retinal vein occlusion (BRVO), who showed mean reductions in CRT (188µm) and MV change (6.1mm^3), patients with central retinal vein occlusion (CRVO) showed greater reductions (135µm and 4.2mm^3, respectively). This indicates possible differences in treatment outcomes based on RVO subtype and raises the possibility that the type of RVO may affect the degree of responsiveness to anti-VEGF medication.

Table 5: Variations in Visual Acuity Depending on OCT Parameters: This table shows the correlation between increases in visual acuity, as measured by the number of gained lines, and changes in OCT parameters (CRT and MV). In comparison to patients with no improvement or with minor improvements, those who saw a significant improvement of three lines or more in visual acuity had a larger mean reduction in CRT (160µm) and MV change (5.0mm^3). This emphasizes how significant improvements in visual acuity are correlated with larger reductions in retinal thickness/volume, which supports the predictive utility of these OCT parameters for visual prognosis in RVO patients.

Together, these in-depth table data highlight the importance of OCT characteristics in forecasting visual outcomes and customizing treatment plans for individuals suffering from RVO.

Table 1: Baseline Characteristics of RVO Patients

Parameter	Mean ± SD (Range)
Age (years)	58.4 ± 7.2 (42-71)
Duration of RVO (months)	8.6 ± 3.1 (4-14)
Baseline CRT (µm)	510 ± 30.4
Baseline MV (mm^3)	9.7 ± 1.8

Table 2: Changes in OCT Parameters Post Anti-VEGF Treatment

Time Point (Weeks)	Mean CRT Reduction (µm)	Mean MV Change (mm^3)
4	82 ± 15	2.5 ± 0.8
8	128 ± 20	3.9 ± 1.2
12	175 ± 25	5.7 ± 1.5

Table 3: Correlation between OCT Parameters and Visual Acuity Improvement

OCT Parameter	Pearson's Correlation Coefficient (r)	p-value
Post-injection CRT Reduction	0.72	<0.001
Post-injection MV Change	0.68	<0.001

Table 4: Subgroup Analysis Based on RVO Type

RVO Type (BRVO/CRVO)	Mean CRT Reduction (µm)	Mean MV Change (mm^3)
BRVO	135 ± 18	4.2 ± 1.1
CRVO	188 ± 22	6.1 ± 1.7

Table 5: Visual Acuity Changes Based on OCT Parameters

Visual Acuity Improvement (Lines)	CRT Reduction (µm)	MV Change (mm^3)
≥3	160 ± 25	5.0 ± 1.3
1-2	95 ± 12	3.0 ± 0.9
None	40 ± 8	1.5 ± 0.5

DISCUSSION

The results of this investigation highlight the critical role that optical coherence tomography (OCT) characteristics play as prognostic biomarkers for visual prognosis in patients receiving anti-vascular endothelial growth factor (anti-VEGF) therapy for RVO.

Interpretation of the Results

The reductions in macular volume (MV) and central retinal thickness (CRT) that were seen after anti-VEGF treatment are consistent with other research, demonstrating the effectiveness of this therapeutic strategy in lessening retinal edema and the morphological alterations linked to RVO. [1]. The 12-week

period's gradual decline in CRT and MV supports the anti-VEGF therapy's long-term benefit in enhancing retinal architecture.

Relationship to Improved Visual Acuity

The therapeutic significance of these OCT parameters is supported by the significant positive correlation observed between improvements in visual acuity and post-treatment reductions in CRT and MV. Significant gains in visual acuity were consistently associated with larger reductions in retinal thickness and volume. These results highlight how OCT parameters can be used to predict visual outcomes, which can help clinicians make decisions about therapy and prognosis [2].

Treatment Response Variations by Subgroup: Treatment responses were found to change depending on the kind of RVO (central retinal vein occlusion, or CRVO) and branch retinal vein occlusion (BRVO). Patients with CRVO showed significantly lower CRT and MV than patients with BRVO. The requirement for specialized treatment approaches that take into account the unique pathophysiological mechanisms behind BRVO and CRVO is highlighted by the disparity in treatment response dependent on RVO subtype [3].

Significances for Medical Practice

The results of the research have important ramifications for clinical practice. First off, OCT has the potential to be a useful predictive tool for determining treatment response and directing therapeutic measures, as evidenced by the correlations between OCT parameters and improvements in visual acuity. Second, understanding the different reactions according to RVO subtype highlights the significance of individualized treatment plans catered to specific patient traits.

Comparative Analysis with Existing Literature: current results are in line with earlier research, as evidenced by the relationships found between OCT parameters and visual outcomes in RVO patients receiving anti-VEGF medication [4]. On the other hand, by identifying subgroup differences and the various effects of anti-VEGF treatment according to RVO type, this research provides more detailed insights.

Integration of OCT data in Clinical Decision-Making: This research's conclusions support the use of OCT data as essential elements in the clinical evaluation of patients with RVO. The usefulness of OCT as a non-invasive method for tracking treatment response and forecasting visual outcomes is shown by the strong correlations found between changes in CRT, MV, and visual acuity. Including these criteria in routine evaluations may help medical professionals create customized treatment plans and improve patient outcomes.

Developments in Imaging Modalities: Although the main focus of this research is on OCT, there are opportunities for thorough examination in RVO due to the growing field of imaging modalities. Retinal pathology can be better understood by combining OCT with additional imaging modalities as fluorescein angiography, adaptive optics, or wide-field imaging. This can improve prognostic indicators and therapy monitoring.

Clinical Consequences for Patient Treatment

The potential to forecast visual prognosis using OCT measurements has significant consequences for patient expectations and counseling. Strong prognostic tools enable clinicians to provide patients with more precise information about what to expect from their treatments, improving patient-doctor communication and enabling patients to make well-informed decisions about their course of care and follow-up appointments [5-7].

Prospective Routes for Research

Prospective studies that have larger cohorts and longer follow-up periods are necessary in the future to confirm and improve the predictive utility of OCT parameters in RVO. Investigating other OCT-derived metrics, like perfusion density or retinal layer thickness, may provide more detailed information on the course of the disease and how well a treatment is working. Furthermore, more research should be done to determine whether anti-VEGF therapy and other modalities—like steroids or laser treatments—have any synergistic effects [8-10].

Clinical Implementation Challenges: Although OCT parameters show great promise, there are still obstacles in the way of their general clinical application. Ensuring equitable adoption of this technology for all patients with RVO requires addressing obstacles related to accessibility, cost, and standardization of imaging procedures across various healthcare settings.

Limitations and Future Prospects

There are a few restrictions that should be noted. The research's limited sample size may restrict the research's capacity to be broadly applied. Furthermore, the observational design of the research limits the ability to demonstrate causality. Subsequent investigations may investigate multimodal imaging and longitudinal evaluations to better clarify the predictive significance of OCT characteristics in RVO prediction.

CONCLUSION

The importance of optical coherence tomography (OCT) measures as predictive biomarkers for determining visual prognosis in patients with RVO receiving anti-vascular endothelial growth factor (anti-VEGF) therapy is highlighted by this research. The potential of OCT in prognosticating treatment success is highlighted by the observed connections between post-treatment decreases in central retinal thickness (CRT), macular volume (MV), and improvements in visual acuity.

The results underscore OCT's clinical utility as a non-invasive means of tracking alterations in retinal morphology and forecasting visual consequences in RVO. Including OCT data in routine evaluations may help doctors better understand their patients' needs and provide individualized treatment plans.

Nonetheless, it is important to take into account the research's limitations, which include sample size restrictions and the observational character of the research. In order to enable greater accessibility and standardization of OCT in clinical practice, future efforts should concentrate on larger-scale research with longer follow-up periods, investigating new OCT measures, and resolving implementation issues.

Essentially, using OCT-derived biomarkers holds potential for improving prognostication and optimizing therapeutic interventions for patients suffering from retinal vascular occlusion, opening the door to more individualized and accurate treatment plans.

REFERENCES

1. Campochiaro, P. A., Heier, J. S., Feiner, L., et al. (2010). Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. *Ophthalmology, 117*(6), 1102-1112.
2. Brown, D. M., Campochiaro, P. A., Singh, R. P., et al. (2010). Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. *Ophthalmology, 117*(6), 1124-1133.
3. Jaulim, A., Ahmed, B., Khanam, T., Chatziralli, I. P. (2013). Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. *Retina, 33*(5), 901-910.
4. Wong, T. Y., Scott, I. U. (2010). Clinical practice. Retinal-vein occlusion. *New England Journal of Medicine, 363*(22), 2135-2144.
5. Campochiaro, P. A., Brown, D. M., Awh, C. C., Lee, S. Y., Gray, S., Saroj, N., Murahashi, W. Y., & Rubio, R. G. (2011). Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. *Ophthalmology*, *118*(10), 2041–2049. https://doi.org/10.1016/j.ophtha.2011.02.038
6. Tan, T. E., Ibrahim, F., Chandrasekaran, P. R., & Teo, K. Y. C. (2023). Clinical utility of ultra-widefield fluorescein angiography and optical coherence tomography angiography for retinal vein occlusions. *Frontiers in medicine*, *10*, 1110166. https://doi.org/10.3389/fmed.2023.1110166
7. Kiire, C. A., & Chong, N. V. (2012). Managing retinal vein occlusion. *BMJ (Clinical research ed.)*, *344*, e499. https://doi.org/10.1136/bmj.e499
8. Thomas, G. N., Kiew, S. Y., Singh, P., Dmitriev, P., Thomas, A. S., & Fekrat, S. (2021). Central Retinal Vein Occlusion: The Effect of Antiplatelet and Anticoagulant Agents. *Journal of vitreoretinal diseases*, *6*(2), 97–103. https://doi.org/10.1177/24741264211028508
9. Hayreh S. S. (2014). Ocular vascular occlusive disorders: natural history of visual outcome. *Progress in retinal and eye research*, *41*, 1–25. https://doi.org/10.1016/j.preteyeres.2014.04.001
10. Singh, P. P., Borkar, D. S., Robbins, C. B., Kim, J. S., Birnbaum, F., Gomez-Caraballo, M., Thomas, A. S., & Fekrat, S. (2021). Systemic antiplatelet agents and anticoagulants in eyes with branch retinal vein occlusion. *Therapeutic advances in ophthalmology*, *13*, 25158414211040894. https://doi.org/10.1177/25158414211040894.

CITATION OF THIS ARTICLE

Anjali D. Patil, Girish A. Gadre and Gaurav H. Khade. Visual Prognosis Prediction in Retinal Vein Occlusion: Insights from Optical Coherence Tomography Biomarkers. Bull. Env. Pharmacol. Life Sci., Spl Issue [2]: 2023: 371-375.